Last updated: September 9, 2026
IPOL is Sanofi Pasteur’s inactivated poliovirus vaccine (IPV), marketed in the United States as a standalone injectable vaccine. Its commercial profile is mature and procurement-driven rather than patent-driven. IPOL has no publicly disclosed product-level revenue, meaningful remaining regulatory exclusivity, or visible biosimilar threat. Financial performance depends on U.S. childhood immunization demand, public-sector purchasing, combination-vaccine competition, global polio-eradication programs, manufacturing continuity, and Sanofi’s broader vaccines portfolio.
What is IPOL and who markets it?
IPOL is a trivalent inactivated poliovirus vaccine containing inactivated poliovirus types 1, 2, and 3. Sanofi Pasteur, the vaccines division of Sanofi, is the manufacturer and U.S. license holder. The product is administered by injection and is used for routine childhood immunization and certain travel or outbreak-related indications.[1]
The U.S. product is supplied as a single-antigen IPV rather than as a combination vaccine. Competing U.S. products include:
| Product |
Manufacturer |
IPV status |
Commercial position |
| IPOL |
Sanofi Pasteur |
Standalone IPV |
Primary U.S. single-antigen IPV product |
| Kinrix |
GSK |
IPV combined with DTaP |
Booster-age combination vaccine |
| Quadracel |
Sanofi Pasteur |
IPV combined with DTaP |
Booster-age combination vaccine |
| Vaxelis |
Sanofi Pasteur, Merck, with other partners |
IPV in hexavalent vaccine |
Infant combination vaccine |
| Pentacel |
Sanofi Pasteur |
IPV in combination vaccine |
Pediatric combination vaccine |
IPOL therefore competes both directly as a standalone IPV and indirectly with combination products that reduce the need for separate injections.
What is the FDA regulatory status of IPOL?
IPOL is an FDA-licensed biologic vaccine. The FDA approved the product in 1987, and the current prescribing information identifies it as an inactivated poliovirus vaccine manufactured by Sanofi Pasteur.[1]
The U.S. recommended IPV schedule generally consists of four doses at ages 2 months, 4 months, 6 through 18 months, and 4 through 6 years. The schedule can vary for catch-up vaccination, travel, outbreak response, and special clinical circumstances.[2]
IPOL’s regulatory status is mature:
| Regulatory factor |
IPOL status |
| FDA pathway |
Biologics license |
| Product type |
Inactivated viral vaccine |
| Administration |
Intramuscular or subcutaneous injection, according to labeling |
| U.S. indication |
Active immunization against poliomyelitis |
| FDA approval |
1987 |
| Pediatric schedule |
Four-dose IPV series in routine U.S. immunization |
| Biologic exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Biosimilar relevance |
Low |
| Orange Book status |
Not the principal federal listing mechanism for this vaccine |
The FDA’s Orange Book primarily identifies approved drug products and patent or exclusivity information under the Hatch-Waxman framework. Licensed vaccines such as IPOL are regulated as biologics through the Public Health Service Act and FDA’s Center for Biologics Evaluation and Research. IPOL’s commercial protection is therefore based on licensure, manufacturing capability, quality systems, supply reliability, and market access rather than current Orange Book patent exclusivity.
When does IPOL lose exclusivity?
IPOL’s original regulatory exclusivity expired decades ago. A product approved in 1987 is outside the five-year new biological entity exclusivity period that would apply under modern biologic frameworks. Any original patent protection would also have expired, assuming conventional filing and patent-term rules.
No current, commercially material IPOL-specific patent term is publicly established as a barrier to competing IPV supply. The relevant distinction is between:
- The historic product and process patents associated with IPV.
- Later patents covering specific combination vaccines, adjuvants, containers, delivery systems, or manufacturing improvements.
- Trade secrets and know-how involving virus culture, inactivation, purification, quality control, potency testing, and production scale.
For a mature vaccine such as IPOL, manufacturing know-how can be more difficult to replicate than the expired composition claims. A competing manufacturer must establish a licensed production process, validated inactivation controls, consistent antigen potency, sterility, stability, and lot-release testing.
What patents protect IPOL?
Publicly available commercial information does not identify a current, enforceable IPOL patent estate that creates material U.S. entry barriers. The product’s core composition is old, and its original approval predates modern biologic exclusivity regimes.
Potentially relevant intellectual-property categories include:
| IP category |
Relevance to IPOL |
| Core IPV composition |
Historic technology; no apparent current exclusivity |
| Poliovirus strains |
May involve legacy strain ownership, biological materials, or licensing rights |
| Inactivation process |
Potentially valuable process know-how, but not necessarily patent-protected |
| Purification and formulation |
May support quality and manufacturing consistency |
| Container and presentation |
Possible secondary protection, usually narrow |
| Combination vaccines |
Separate patent and regulatory analysis |
| Manufacturing cell systems |
Potentially important to process development and scale |
| Quality-control methods |
May be confidential or protected by know-how |
Sanofi’s stronger strategic protection is likely concentrated in manufacturing infrastructure, regulatory records, supply-chain capability, and combination-vaccine products rather than in a live patent monopoly over standalone IPOL.
How strong is the IPOL patent estate?
The IPOL patent estate is weak as a standalone exclusivity asset but stronger as an operational and regulatory asset.
A practical assessment is:
| Protection category |
Strength |
Commercial effect |
| Core composition patents |
Low |
No apparent current barrier |
| Regulatory exclusivity |
None of material duration |
Does not block entry |
| Manufacturing know-how |
Moderate to high |
Can delay reliable competition |
| FDA product history |
High operational value |
Supports quality and regulatory maintenance |
| Brand recognition |
Moderate |
Helps preserve institutional demand |
| Distribution and procurement access |
Moderate to high |
Important in public tenders |
| Combination-vaccine portfolio |
Higher than standalone IPOL |
Protects broader pediatric franchise |
A competitor could theoretically develop and license an alternative IPV without infringing an active IPOL composition patent. The practical challenge is proving equivalence, securing manufacturing capacity, and obtaining predictable procurement volume.
What is the market outlook for IPV and IPOL?
The global IPV market has two distinct segments:
U.S. routine immunization
The U.S. market is stable because IPV remains part of the standard childhood vaccination schedule. Demand is recurring but relatively predictable. Volume growth is limited by birth cohorts, vaccination coverage, catch-up campaigns, and public-health responses.
Sanofi benefits from selling both IPOL and combination vaccines. This reduces reliance on the standalone product but also means that demand for IPOL can shift toward Kinrix, Quadracel, Vaxelis, or Pentacel when providers prefer fewer injections.
Global polio-eradication procurement
The global market is more procurement-sensitive. Governments, UNICEF, the Global Polio Eradication Initiative, Gavi, and other public-health organizations influence volume, pricing, and product selection.[3][4]
Global IPV demand has been supported by the transition from oral poliovirus vaccine programs toward schedules that include IPV. The eradication program has also used fractional-dose IPV and outbreak-response strategies in selected settings. These programs can generate large orders, but they are exposed to tender pricing, donor funding, supply allocation, and changing vaccination policy.
Market drivers
Key market drivers include:
- Continued inclusion of IPV in national immunization schedules.
- Polio outbreak response and surveillance findings.
- Introduction or expansion of fractional-dose IPV programs.
- Public-sector procurement by UNICEF, Gavi, and national ministries.
- Vaccine stockpiling and supply-resilience policies.
- Birth-cohort growth in emerging markets.
- Product preference for combination vaccines in high-income markets.
Market constraints
The main constraints are:
- Mature demand in the United States and Western Europe.
- Public-tender pricing pressure.
- Competition from combination vaccines.
- Manufacturing complexity and limited qualified suppliers.
- Procurement concentration among governments and international agencies.
- Potential use of lower-cost IPV suppliers in emerging markets.
What is IPOL’s financial trajectory?
Sanofi does not publicly report IPOL revenue as a separate line item in its annual reporting. The product is included within a broader vaccines business that contains multiple products, territories, and contractual channels. As a result, the following metrics are not publicly disclosed at the IPOL level:
- Annual IPOL net sales.
- IPOL gross margin.
- IPOL operating profit.
- U.S. versus international revenue.
- Public-sector versus private-sector sales.
- Product-specific volume.
- Product-specific price realization.
Sanofi’s vaccines business has been affected by portfolio mix, pediatric vaccines, influenza products, travel vaccines, COVID-19 products, and public-health procurement. IPOL’s financial trajectory should therefore be modeled as a mature, low-growth product within a larger vaccines platform rather than as a separately reported growth asset.[5]
| Financial factor |
Expected effect on IPOL |
| U.S. birth cohort |
Stable baseline demand |
| Combination-vaccine substitution |
Negative for standalone volume |
| Public tenders |
Negative for price realization |
| Outbreak response |
Positive but episodic |
| Global eradication procurement |
Positive volume opportunity, variable margin |
| Manufacturing disruptions |
Potentially material revenue risk |
| Patent expiry |
Limited incremental effect because exclusivity is already expired |
| Product withdrawal risk |
Low if manufacturing and supply remain compliant |
| Sanofi portfolio strategy |
Could affect promotion, allocation, or supply emphasis |
The most likely trajectory is stable-to-moderately declining standalone demand in markets where combination vaccines gain share, offset by durable institutional demand and periodic international procurement. Revenue volatility is more likely to come from tender timing and supply allocation than from patent events.
Which companies are challenging IPOL?
No major U.S. Paragraph IV challenge against IPOL is publicly established as a central market event. Paragraph IV litigation is generally associated with abbreviated new drug applications and Orange Book-listed patents. IPOL is a licensed biologic vaccine, so the classic Hatch-Waxman Paragraph IV pathway is not the principal competitive mechanism.
Potential competitors operate through different regulatory and commercial routes:
- Licensed IPV manufacturers supplying national programs.
- Combination-vaccine manufacturers.
- International suppliers competing for UNICEF and ministry tenders.
- Manufacturers of novel or fractional-dose IPV products.
- Producers of oral poliovirus vaccines in programs where OPV remains authorized.
Relevant global competitors can include manufacturers such as Bharat Biotech, Serum Institute of India, Bilthoven Biologicals, Bio-Med, Panacea Biotec, and other regionally licensed suppliers. Competitive presence varies by country and by procurement qualification. A product’s presence in a global tender does not establish U.S. approval or direct substitutability for IPOL.
What formulation patents and method-of-use rights matter?
Standalone IPOL is an established aqueous injectable vaccine. The principal commercial issues are antigen content, inactivation, sterility, potency, stability, storage, and presentation. Secondary patents may cover:
- Combination formulations containing IPV.
- Multi-dose or single-dose presentations.
- Stabilizers and excipients.
- Container systems and prefilled syringes.
- Fractional-dose administration.
- Immunization schedules and outbreak-response use.
- Manufacturing, purification, and quality-control processes.
Method-of-use patents are unlikely to create a significant barrier for routine IPV immunization because the basic indication is longstanding. More recent intellectual property could be relevant to fractional-dose strategies, delivery devices, or combination-product formulations, but those rights would not necessarily block a conventional full-dose standalone IPV.
What generic entry risks exist for IPOL?
The “generic” risk is limited in the conventional small-molecule sense. A competing manufacturer would more likely pursue a separate biologic license or applicable abbreviated pathway than an ordinary ANDA.
The main entry scenarios are:
Scenario 1: No meaningful new U.S. standalone competitor
Sanofi retains a strong position because IPV manufacturing is specialized, demand is moderate, and the commercial return may not justify the development and validation expense for a new U.S. supplier.
Scenario 2: Combination-vaccine substitution
Standalone IPOL volume declines gradually as pediatric providers use combination products. This is the most credible persistent competitive pressure in the U.S. market.
Scenario 3: International tender displacement
Lower-cost suppliers win government or donor-funded contracts outside the United States. This can reduce Sanofi’s international volume without affecting U.S. clinical use.
Scenario 4: Supply-driven share changes
Manufacturing interruptions, lot-release delays, or allocation decisions can temporarily redirect demand to alternative IPV or combination-vaccine products.
Scenario 5: New IPV technologies
Novel production systems, fractional-dose approaches, or improved delivery formats could create price or supply advantages. Adoption would depend on clinical evidence, WHO prequalification, national licensure, and procurement approval.
What litigation and settlement agreements affect IPOL?
No major current patent litigation or settlement agreement is publicly identified as a defining commercial issue for IPOL. The product’s age and biologic regulatory pathway reduce the likelihood that conventional Paragraph IV litigation will determine market entry.
Litigation risk is more likely to arise from:
- Manufacturing and supply contracts.
- Product liability claims.
- Regulatory compliance or lot-release issues.
- Procurement disputes.
- Intellectual property associated with combination vaccines or manufacturing technology.
- Contractual disputes involving international tenders.
The absence of a visible IPOL-specific patent case means the principal business risks are operational and commercial rather than litigation-driven.
How does IPOL compare with combination IPV vaccines?
| Factor |
IPOL |
Combination IPV vaccines |
| Product format |
Standalone IPV |
IPV plus other pediatric antigens |
| Main use |
Primary IPV vaccination, catch-up, special situations |
Routine pediatric schedules and booster doses |
| Injection burden |
Higher when other vaccines are needed |
Lower |
| Commercial growth |
Mature |
More favorable where combination adoption rises |
| Patent complexity |
Older, limited standalone estate |
Potentially newer formulation and combination claims |
| Procurement role |
Useful as a flexible single-antigen product |
Preferred for schedule simplification |
| Revenue durability |
Stable but exposed to substitution |
Stronger portfolio integration |
| Main risk |
Combination displacement |
Manufacturing complexity and competitive combination products |
Sanofi’s ownership of both IPOL and major combination vaccines gives it portfolio protection. A decline in standalone IPOL does not necessarily represent a proportional loss of Sanofi IPV revenue if demand shifts to Quadracel, Vaxelis, or Pentacel.
What geographic markets matter most?
The United States is strategically important because of stable routine immunization and established reimbursement channels. Europe and other high-income markets are shaped by national procurement and combination-vaccine preferences.
Emerging markets can offer greater volume but lower pricing. Their value depends on:
- National immunization schedules.
- Gavi eligibility.
- UNICEF or other pooled procurement.
- Local registration.
- WHO prequalification.
- Tender competitiveness.
- Cold-chain capacity.
- Outbreak-response requirements.
The strongest commercial position is not necessarily tied to the highest unit price. For IPV, regulatory qualification and procurement access can matter more than brand awareness.
Key Takeaways
- IPOL is Sanofi Pasteur’s mature standalone inactivated poliovirus vaccine.
- FDA approval dates to 1987, and meaningful regulatory exclusivity has expired.
- No current IPOL-specific patent estate appears to create a material U.S. market barrier.
- IPOL is not primarily exposed to classic Paragraph IV generic litigation.
- Sanofi does not disclose IPOL-specific revenue or profit.
- Standalone U.S. demand is stable but faces substitution from combination vaccines.
- Global revenue depends heavily on public procurement, tenders, eradication programs, and supply availability.
- Manufacturing know-how, quality systems, and regulatory history are more important than patent exclusivity.
- The main competitive risks are combination-vaccine substitution, lower-cost international suppliers, tender pricing, and supply disruptions.
- Sanofi’s broader pediatric vaccine portfolio reduces the financial impact of standalone IPOL volume changes.
FAQs
Is IPOL still commercially available in the United States?
IPOL remains an FDA-licensed standalone IPV product marketed by Sanofi Pasteur, subject to current supply and distribution conditions.
Is IPOL interchangeable with Kinrix or Quadracel?
IPOL contains IPV alone, while Kinrix and Quadracel combine IPV with other pediatric antigens. Clinical substitution depends on the patient’s immunization schedule and applicable CDC and FDA guidance.
Does IPOL have biosimilar competition?
No conventional biosimilar competition is a central commercial issue for IPOL. Competing IPV products would generally require their own biologic licensing and manufacturing validation.
Is IPOL listed in the FDA Orange Book?
Vaccines such as IPOL are principally regulated and documented through the biologics framework rather than the Orange Book’s conventional small-molecule patent-listing system.
What is the largest long-term risk to IPOL revenue?
The largest persistent risk is gradual substitution by combination vaccines, followed by public-tender price pressure and competition from qualified international IPV manufacturers.
References
-
U.S. Food and Drug Administration. (2024). IPOL: Inactivated poliovirus vaccine, prescribing information. Sanofi Pasteur Inc.
-
Centers for Disease Control and Prevention. (2024). Child and adolescent immunization schedule by age. U.S. Department of Health and Human Services.
-
Global Polio Eradication Initiative. (2024). Polio vaccines and vaccination strategies. World Health Organization.
-
United Nations Children’s Fund. (2024). Polio vaccine supply and procurement. UNICEF Supply Division.
-
Sanofi. (2024). Universal registration document and annual financial report 2023. Sanofi S.A.
